WALTHAM, Mass., Oct. 24, 2017 /PRNewswire/ -- SHYFT Analytics, the leading data and analytics cloud for life sciences, today announced that in
"More than half of newly launched drugs fail to meet market expectations. The success rate is even lower with Rare Disease and Specialty therapies, where smaller patient populations and complicated delivery make successful commercialization a challenge," said Zack King, founder and CEO at SHYFT. "The SHYFT Platform is designed to overcome these challenges and is becoming the technology foundation for drug launches in life sciences. This allows our customers to drive greater efficiency and focus on innovation, not infrastructure as they launch important new therapies."
SHYFT's Launch Solution has seen increased adoption across customers, including four of the twenty largest biopharmaceutical companies. Rare and Specialty brands face unique challenges when launching new therapies, especially with regards to managing and making sense of complex data. They must manage a broad spectrum of distribution, commercial, and patient-level data to measure market execution and patient outcomes. The SHYFT Platform seamlessly integrates hundreds of data sources, including provider, payer, prescription, claims, and EMR data, into a unified cloud data platform answering complex clinical and commercial queries in minutes. Customers use SHYFT's cloud platform and mobile analytic products to collaborate and engage their customers, identify and onboard patients, understand prescribing influences, and optimize treatment adherence and outcomes – a major transformation from legacy on-premise and expensive consulting-based solutions.
About SHYFT SHYFT Analytics is the leading analytics cloud platform for life sciences with products and solutions designed specifically for the unique pharmaceutical, biotech, and medical device industry. SHYFT's Data Analytics Platform is the most efficient and scalable way to transform massive amounts of complex healthcare data into on-demand clinical and commercial insight. SHYFT is headquartered in Boston with offices in San Francisco and New York City. Learn more about SHYFT at www.shyftanalytics.com, or follow the company on Twitter @SHYFTAnalytics or LinkedIn.
View original content:http://www.prnewswire.com/news-releases/six-new-companies-select-shyft-to-maximize-launch-success-of-specialty-and-rare-disease-brands-300541870.html
SOURCE SHYFT Analytics
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All